NASDAQ: NAUTNautilus Biotechnology Inc Stock
$2.93+0.18 (+6.55%)
Updated Dec 1, 2023
NAUT Price
$2.93
Fair Value Price
N/A
Market Cap
$366.09M
52 Week Low
$1.50
52 Week High
$4.65
P/E
-6.1x
P/B
1.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$60.06M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$48M
Beta
1.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NAUT Overview
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NAUT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NAUT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NAUT is good value based on its book value relative to its share price (1.32x), compared to the US Biotechnology industry average (5.42x)
P/B vs Industry Valuation
NAUT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NAUT due diligence checks available for Premium users.
Be the first to know about important NAUT news, forecast changes, insider trades & much more!
NAUT News
Valuation
NAUT fair value
Fair Value of NAUT stock based on Discounted Cash Flow (DCF)
Price
$2.93
Fair Value
$2.97
Undervalued by
1.48%
NAUT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NAUT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.1x
Industry
11.49x
Market
29.49x
NAUT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.32x
Industry
5.42x
NAUT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NAUT's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.9M
Profit Margin
0%
NAUT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$318.3M
Liabilities
$41.1M
Debt to equity
0.15
NAUT's short-term assets ($186.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAUT's short-term assets ($186.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAUT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.7M
Investing
$13.1M
Financing
$16.0k
NAUT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NAUT vs Biotech Stocks
Nautilus Biotechnology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.